Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma
This is a single-center, single-arm, open-label Phase I study to evaluate the safety and efficacy of GPC3-CAR-T cell immunotherapy in the treatment of hepatocellular carcinoma.
BIOLOGICAL: GPC3-CAR-T cells
Percentage of adverse events, Percentage of participants with adverse events., 3months
This study is a single-center, dose-escalation, prospective, exploratory study to evaluate the safety and efficacy of GPC3 CAR-T cells in subjects with hepatocellular carcinoma. The study was divided into two phases: dose escalation and dose expansion. The total study duration is expected to be 2 years. The total time for each subject to participate in the study is expected to be more than 1 year, including the screening period, non-myeloablative chemotherapy pretreatment, cell infusion-observation period, follow-up period, and then enter the survival follow-up, followed by telephone follow-up every 2 months, Collect subject survival information.